NCT05139472View on ClinicalTrials.gov

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

September 20, 2023

Study Completion Date

February 19, 2024

Conditions
Heart Failure with Preserved Ejection FractionHeart Failure, DiastolicDiabetes Mellitus
Interventions
DRUG

Empagliflozin 10 MG

Daily Empagliflozin

Trial Locations (2)

75231

Institute for Exercise and Environmental Medicine, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT05139472 - Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter